Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-30T05:43:23.219Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1569 - The Pharmacological Management of Obsessive Compulsive Disorder: The Evidence from Published Meta-analyses

Published online by Cambridge University Press:  15 April 2020

P. Skapinakis ,
H. Baxter ,
D. Caldwell ,
R. Churchill ,
N. Fineberg  and
G. Lewis
P. Skapinakis
Affiliation:
Mental Health Sciences Unit, University College London, London, United Kingdom
H. Baxter
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
D. Caldwell
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
R. Churchill
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
N. Fineberg
Affiliation:
Queen Elizabeth II Hospital, Hertfordshire Partnerships Mental Health Trust, Welwyn Garden City, United Kingdom
G. Lewis
Affiliation:
Mental Health Sciences Unit, University College London, London, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

The aim of this presentation is to summarize the results of the published systematic reviews / meta-analyses of the randomized controlled trials that have investigated the effectiveness of medications for the treatment of obsessive compulsive disorder (OCD) in children/adolescents and adults and to present preliminary results from a new review study using network meta-analytical techniques

Methods

Medline, Cochrane database, and the register of controlled trials maintained by the Cochrane Collaboration Depression, Anxiety & Neurosis Group (CCDAN) were searched for relevant trials, systematic reviews and/or meta-analyses.

Results

Regarding the new review study we were able to extract 103 pharmacological arms (preliminary results: 9 for Fluoxetine, 16 for Fluvoxamine, 11 for Paroxetine, 10 for Sertraline, 16 for Clomipramine, 7 for Citalopram / escitalopram, 2 for Venlafaxine, and 32 for Placebo) with a total number of 6572 patients randomized. The previous meta-analyses have confirmed the efficacy for all SSRIs and Clomipramine in all age groups while for other drugs further evidence is required. In the context of this presentation preliminary results of the relative efficacy of each drug, using network meta-analysis techniques will also be reported.

Conclusions

Several antidepressants have established their efficacy and acceptability for the management of non-resistant OCD. The major weakness of the literature so far is that head to head comparisons between antidepressants are few and therefore it is difficult to establish a clear hierarchy of the efficacy and acceptability of the various agents. This gap in the present literature will be filled by the present review.

Type
S543 - The meta-analytic studies in Psychiatry: have we learned anything?
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.